Abstract | BACKGROUND: AIM: METHOD: In a double-blind randomized study, 59 active ulcerative colitis patients received Predocol 40 mg/day for 6 months, 61 received Predocol 60 mg/day for 6 months and 61 received prednisolone 40 mg/day for 2 weeks, tapered to week 8, followed by placebo until 6 months. RESULTS:
Steroid-related side effects assessed using a 10-cm visual analogue scale were fewer at 2 months with Predocol 40 mg [VAS 8.1 cm (2.6), mean (s.d.)], or 60 mg [8.1 (2.1)] compared with prednisolone [6.7 (2.7); P = 0.01]. Mood changes affected 43% receiving prednisolone at 4 weeks vs. 8% for Predocol 40 mg (P = 0.001). Remission rates (Powell-Tuck < or =2) at 2 months were Predocol 40 mg 46%, Predocol 60 mg 28% and tapering prednisolone 41% (P = 0.13). Visual analogue scale for efficacy also showed non-inferiority for Predocol 40 mg/day. Remission rates at 6 months were Predocol 40 mg 51%, Predocol 60 mg 38% and tapering prednisolone 32% (P = 0.08). CONCLUSION: Predocol 40 mg/day has similar efficacy but markedly fewer side effects than a conventional tapering prednisolone regimen (ISRCTN14133410).
|
Authors | J M Rhodes, R Robinson, I Beales, S Pugh, R Dickinson, M Dronfield, C J Speirs, P Wilkinson, S P Wilkinson |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 27
Issue 3
Pg. 228-40
(Feb 01 2008)
ISSN: 1365-2036 [Electronic] England |
PMID | 17988236
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- prednisolone 21-3-sulfobenzoate
- Prednisolone
|
Topics |
- Adult
- Aged
- Anti-Inflammatory Agents
(administration & dosage, adverse effects)
- Chi-Square Distribution
- Colitis, Ulcerative
(drug therapy)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prednisolone
(administration & dosage, adverse effects, analogs & derivatives)
- Pulse Therapy, Drug
- Statistics, Nonparametric
- Treatment Outcome
|